To include your compound in the COVID-19 Resource Center, submit it here.

Alexion augmenting pipeline with Zealand, Affibody deals

Alexion took a pair of steps toward further rebuilding its pipeline Wednesday, gaining rights to targets in the complement pathway via a deal with Zealand and adding a clinical-stage molecule from Affibody for IgG-mediated autoimmune diseases.

The deal with Zealand Pharma A/S

Read the full 413 word article

Trial Subscription

Get a two-week free trial subscription to BioCentury

SIGN UP

Article Purchase

This article may not be distributed to non-subscribers
More Info >PURCHASE